Mechanisms of skeletal muscle atrophy
- 1 November 2006
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Rheumatology
- Vol. 18 (6), 631-635
- https://doi.org/10.1097/01.bor.0000245731.25383.de
Abstract
Recent clinical and mechanistic studies have shown that increased proteolysis is a major determinant of muscle wasting in numerous catabolic states and of alterations in myopathies or dystrophies. The implications of these observations for improving muscle mass and function are discussed. Several proteolytic systems (i.e. the ubiquitin-proteasome system, the lysosomal, the Ca-dependent, and the caspase systems) are responsible for muscle wasting. The Ca-dependent and caspase systems may initiate myofibrillar proteolysis. The ubiquitin-proteasome system is believed to degrade actin and myosin heavy chain and, consequently, plays a major role in muscle wasting. Multiple steps in the ubiquitin-proteasome system (ubiquitination, deubiquitination, proteasome activities) are upregulated in muscle wasting diseases. Few key components of the ubiquitin-proteasome system that are strictly necessary for muscle wasting have been so far characterized. Recent studies have led to the elucidation of various signaling pathways of the ubiquitin-proteasome system that are activated in muscle wasting conditions. Although the precise role of the different muscle proteolytic machineries is still largely unknown, current studies are leading to new pharmacologic approaches that can be useful in blocking or partially preventing muscle wasting or improving muscle function in human patients.Keywords
This publication has 35 references indexed in Scilit:
- Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expressionAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2006
- Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatmentAmerican Journal of Physiology-Cell Physiology, 2006
- A signaling role for dystrophin: Inhibiting skeletal muscle atrophy pathwaysCancer Cell, 2005
- Control of ubiquitination in skeletal muscle wastingThe International Journal of Biochemistry & Cell Biology, 2005
- Skeletal muscle hypertrophy and atrophy signaling pathwaysThe International Journal of Biochemistry & Cell Biology, 2005
- Lysosomal proteolysis in skeletal muscleThe International Journal of Biochemistry & Cell Biology, 2005
- Degradation of MyoD Mediated by the SCF (MAFbx) Ubiquitin LigaseOnline Journal of Public Health Informatics, 2005
- The molecular basis of skeletal muscle atrophyAmerican Journal of Physiology-Cell Physiology, 2004
- Identification of Ubiquitin Ligases Required for Skeletal Muscle AtrophyScience, 2001
- No alteration in gene expression of components of the ubiquitin proteasome proteolytic pathway in dystrophin-deficient musclesFEBS Letters, 1996